SWISS-MEDICAL-GROUP
Swiss Medical Group (SMG) Holding Luxembourg S.A., leading the development of STARKS Age-Management in Europe and Asia, announced today the acquisition of CoreMedica Europe, to expand in Europe and the rest of the world.
CoreMedica Europe recently made the headlines in Switzerland for combining a COVID-19 Screening Test and Immunity profile with its existing home self-collection kit that allows customers to collect a few drops of blood and send them by mail to CoreMedica Europe’s accredited laboratory in Geneva to screen the anti-SARS-COV-2 IgG antibody and assess any previous infection to SARS-COV-2, the virus responsible for COVID disease, and analyze a set of 5 key biomarkers known to support the immune system (vitamin D, zinc, magnesium, copper, selenium) so as to receive personalized actionable recommendations to help patients build up their natural defenses against the effects of a next potential viral infection.
“In this epidemic and containment context the essential objective of CoreMedica Europe is to allow a patient to collect a few drops of blood at home without involving healthcare personnel and to carry out this serology test in a controlled laboratory environment. From 3 drops of blood taken from your fingertip, our test can tell if someone has been infected with the coronavirus in the past and can help to clarify their general immune status by assessing key markers in the blood” says Dr Jean-Marc Leroux, CEO of CoreMedica Europe.
“With this test we are putting our expertise in testing and personalized recommendations at the service of the fight against COVID 19, with a set of key biomarkers known to support someone's immune system and a precise summary of the results so as to help them strengthen their natural defenses against the effects of the next potential viral infection” says Pierre-Edouard Sottas, CSO of CoreMedica Europe.
CoreMedica expertise goes beyond COVID-19 serological testing and its competitive advantage lies in the personalized analysis of biological data on three main axes:
- Collection of health data by means of home self-collection kits of a few drops of blood,
- Analysis of large quantities of bio-markers, with a unique know-how developed over several years,
- Personalized recommendations using patented technology applied in the field of immunity, nutrition, sports, and anti-aging.
“The objective of SMG is to integrate CoreMedica Europe's unique expertise in the field of blood tests and personalized recommendations into the network of anti-aging clinics that SMG is developing in Europe, so as to improve P4 models in the field of anti-aging and foster preventative care, thereby reducing the costs of treatments” , says Francois Marland, Chairman and CEO of Swiss Medical Group and Chairman of CoreMedica Europe.
SMG has already tested the market with age-management clinics in France, Italy and Greece, the on-going development of eight more clinics in Germany in 2020-2021, and a roll-out plan of 52 age-management clinics in Europe by 2025, developed either by organic growth or by the acquisition of well-known practices.
As part of the deal, SMG took over the operations of CoreMedica Europe in Geneva, the team and its expertise, the authorizations, and all associated patents, algorithms and other intellectual property, as well as negotiated an exclusive distribution agreement in North America with CoreMedica Laboratories Inc., a CAP accredited and CLIA certified laboratory based in the United States.
About Swiss Medical Group:
As a backdrop, Swiss Medical Group Holding invests in the development of companies and clinics in the health sector, including STARKS Age Management, whose activity is to offer a one-stop-shop solution in terms of internal and external age management, including hair, aesthetics, orthopedics, blood tests, digital analysis and health maintenance recommendations, as well as the distribution of well-being or anti-aging products, protocols and therapies.
About CoreMedica Europe:
As a background, BioKaizen, founded in Switzerland and born from developers of the athlete biological passport to detect drug use for the World Anti-Doping Agency and the International Olympic Committee, has developed a mass spectrometry technology platform to identify a patient’s nutritional profile using dried blood. Following the merger with BioKaizen in 2018, CoreMedica expanded its offering globally to include personalized nutrition and sport performance information that empowers customers with information to help actively manage their health.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200924005730/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting styrker sit udbud inden for digital transformation med Silver Creek23.1.2026 14:25:00 CET | Pressemeddelelse
Andersen Consulting annoncerer en samarbejdsaftale med Silver Creek, en førende virksomhed inden for datastrategi, analyse, applikationsudvikling og ai-drevne automatiseringstjenester. Silver Creek Software er en førende teknologivirksomhed, der er baseret i Alberta, Canada, med ekspertise i at transformere organisationer gennem data- og forretningsløsninger. Firmaet blev etableret i 1998 og tilbyder komplette konsulentydelser med speciale i data og analyse, applikationsudvikling, maskinlæring og ai. Med et team af erfarne og certificerede fagfolk leverer virksomheden skræddersyede løsninger på tværs af flere brancher, herunder den offentlige sektor, finansielle tjenester, naturressourcer og transport. Kernen i Silver Creeks arbejde er at skabe værdi ud fra kundens data gennem digitalisering, integration og automatisering. "Vi har opbygget vores omdømme på at hjælpe organisationer med at omdanne komplekse dataøkosystemer til strategiske aktiver," udtaler Ben Steem, administrerende dire
DCX Liquid Cooling Systems Announces New 8MW Coolant Distribution Unit, Optimized for 45°C Warm-Water Cooling in Next-Gen NVIDIA Vera Rubin AI Deployments23.1.2026 14:18:00 CET | Press release
DCX beats its own record of the most powerful CDU system ever made. Liquid cooling Manufacturer leads category of hyperscale CDUs, launching today a new CDU system with a stunning 8MW capacity, designed specifically for NVIDIA Vera Rubin 45°C warm water cooling DCX Liquid Cooling Systems is proud to announce the second generation Facility Distribution Unit (FDU V2AT2). Designed to support the infrastructure shift driven by AI deployments at scale, new CDU supports 45°C warm-water cooling for NVIDIA’s NVL72 GB200 / GB300 Blackwell and Vera Rubin architectures. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260123068139/en/ The Facility Coolant Distribution Unit—the new generation of liquid cooling for hyperscale data centers. FDU V2AT2 delivers up to 8.15MW of heat transfer capacity while providing record breaking flowrate, enabling 45°C warm-water operation—temperature level that can eliminate the need for chillers on the he
HUMAIN and Infra Announce AI and Digital Financing Framework Agreement23.1.2026 14:01:00 CET | Press release
HUMAIN and the National Infrastructure Fund (“Infra”) announced on the sidelines of the World Economic Forum (WEF) Annual Meeting 2026 in Davos, Switzerland, a Strategic Financing Framework Agreement of up to $1.2 billion to support the expansion of AI and digital infrastructure projects in the Kingdom of Saudi Arabia. The Framework Agreement outlines non-binding financing terms for HUMAIN’s development of up to 250 MW of hyperscale AI data center capacity. These data centers will deploy leading edge GPUs for AI training and inference and support HUMAIN’s local, regional and global customers. In addition, Infra and HUMAIN have agreed to explore the establishment of an AI data center investment platform. This would be anchored by the two organizations and structured to facilitate participation by global and local institutional investors to support further scaling of HUMAIN’s AI strategy. Today’s Framework Agreement underscores Infra’s key role in partnering with its counterparts to acce
Cyclic Materials Secures USD $75M Series C Funding to Fast-Track Local and Resilient Rare Earths Supply at Global Scale23.1.2026 13:00:00 CET | Press release
New equity investment will accelerate deployment of resilient, locally anchored rare earths recycling infrastructure enabling new streams of heavy rare earths supply for AI, robotics, defense and advanced manufacturing critical to the future of Western industry Cyclic Materials today announced it has closed an over-subscribed USD $75 million Series C equity round, its largest to date, scaling up operations across the US and Europe and accelerating Canada-based research and development footprint. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260123519008/en/ Cyclic Materials’ Mesa, Arizona site, the very first scale-up of a commercial plant for recycling and local production of rare earths in the US, with a focus on heavy and light rare earth magnets. The recycling of magnet-containing end-of-life (EOL) scrap and magnet production waste is the fastest way to the production of magnet rare earth elements (REEs) in Western coun
SLB Announces Fourth-Quarter and Full-Year 2025 Results, Increases Dividend and Commits to Return More Than $4 Billion to Shareholders in 202623.1.2026 12:50:00 CET | Press release
Fourth-quarter revenue of $9.75 billion increased 9% sequentially and 5% year on year Fourth-quarter GAAP EPS of $0.55 increased 10% sequentially and decreased 29% year on year Fourth-quarter EPS, excluding charges and credits, of $0.78 increased 13% sequentially and declined 15% year on year Fourth-quarter net income attributable to SLB of $824 million increased 12% sequentially and decreased 25% year on year Fourth-quarter adjusted EBITDA of $2.33 billion increased 13% sequentially and decreased 2% year on year Fourth-quarter cash flow from operations was $3.01 billion and free cash flow was $2.29 billion Board approved a 3.5% increase in quarterly cash dividend to $0.295 per share Full-year revenue of $35.71 billion decreased 2% year on year Full-year GAAP EPS of $2.35 decreased 24% year on year Full-year EPS, excluding charges and credits, of $2.93 decreased 14% year on year Full-year net income attributable to SLB of $3.37 billion decreased 24% year on year Full-year adjusted EBIT
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom